TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05650229: Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

Sponsor: Pharming Technologies B.V. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 180 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,556,400

Rescue Site Savings

+$1,693,200

Unlock Full NCT05650229 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05650229 Rescue Dossier →